You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
An integrative multi phenotype pipeline for drug evaluation pharmacogenomics and attribute prediction
SBC: PHENVOGEN LLC Topic: 300PROJECT SUMMARY The process of drug discovery is costly and many promising compounds fail during clinical trials By then expenses upward of $ million dollars per failed drug may have incurred and these financial risks hamper research efforts and ultimately reduce the availability of treatment options In this research proposal we are using systematic approaches to map the relationships be ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Oligonucleotide Inhibition for cardiac regeneration in Ischemia
SBC: JAAN BIOTHERAPEUTICS LLC Topic: NHLBIPROJECT SUMMARY Ischemic heart disease IHD is the single largest cause of death worldwide A heart attack or myocardial infarction MI results from limitation of coronary blood flow to the heart causing ischemia and ultimately irreversible death of cardiomyocytes The size of a myocardial infarct correlates with the degree of deterioration of heart function compromise of contractile reserve ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
AutoRegister: A system for enhancing the accuracy of tumor change detection
SBC: CORTICOMETRICS LLC Topic: 102PROJECT SUMMARY This project proposes to continue the development of AutoRegisterTMan integrated software based system for enhancing the accuracy of tumor change detectionThe intent of the system is to automate the alignment of a patient s brain scan with that of a prior scan such that subsequent offline tumor measurements do not have error introduced solely by differing slice orientationsWhile si ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Clinical Translation of Augmented Reality Visualization for Laparoscopic Surgery
SBC: IGI TECHNOLOGIES, INC Topic: 102The overall objective of the proposed research is to develop and conduct clinical translation of a novel visualization technology that provides minimally invasive surgeons the ability to visualize normally invisible internal anatomy together with organ surfacesThe technology addresses a long standing need in minimally invasive laparoscopic surgery to see inside and around a structure before dissec ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Peripheral FAAH as a target for novel analgesics
SBC: Anteana Therapeutics Inc Topic: NIDADESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown that endocannabinoid receptors located outside the central nervous systemCNSexert a powerful regulatory control over pain initiationThe biological actions of anandamide are stopped by the enzymefatty ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing a small peptide to control autoimmune inflammation in type diabetes
SBC: Op-T-Mune, Inc Topic: NIAIDAbstract Type Diabetes T D affects an ever growing population While this disease typically has been associated with juveniles the disease in adult populations is rapidly increasing The defining clinical component is insulin loss which occurs because of sustained inflammation in the islets At present there is no means to prevent or reverse insulin loss A major inflammatory pathway in T D ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A novel anti gonorrhea immunotherapeutic
SBC: Planet Biotechnology Incorporated Topic: NIAIDAntimicrobial resistance is a major public health problem worldwide Neisseria gonorrhoeae Ng the causative agent of the sexually transmitted infection gonorrhea has become multidrug resistant and has achieved superbug status Novel therapeutics against Ng are urgently needed Complement C is a key arm of innate immune defenses A mechanism used by several pathogens including Ng to esca ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
SBC: Integrated Biotherapeutics, Inc. Topic: rProject Summary The Gram positive bacterium Bacillus anthracis is a very strong candidate for potential bioweaponizationand believed to have actually been weaponized by the former Soviet UnionAnthrax spores are readily found in nature or produced in the laboratoryare resistant to harsh conditionsand can survive for a long time in the environmentThe microscopic spores could be formulated in powder ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
In Vivo Editing for Hemophilia Gene Therapy
SBC: GENVEC, INC. Topic: 100Project Summary The exceptional promise of gene therapy for hemophilia has been shown in recent studies that result in long term correction of factor IX deficiency via hepatic transduction with an adeno associated vector AAV In spite of this watershed event in the history of the gene therapy field there presently exist barriers to the fullest implementation of hemophilia gene therapy The li ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDPROJECT SUMMARY The family of Filoviridae consisting of five ebolaviruses and two marburgviruses are causative agents of severe hemorrhagic fever with human case fatality rates ofTheepidemic of Ebola virus disease in West Africa was unprecedented both in geographic scope and size and highlighted the extent of the threat filoviruses could pose to global public health and the urgent need for develop ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health